Lightnews — Scholar-powered news

Reposted by Hashim Ahmed

Imperial Prostate @ip-london.bsky.social · Apr 29

Update of #IP7PACIFIC presented by @ajwlight.bsky.social at #AUA25 🇺🇸

This will be the first trial to provide definitive evidence comparing bpMRI vs mpMRI, alongside fusion vs cognitive biopsy

>1200 patients recruited across the UK - watch this space

1 2 2

Reposted by Hashim Ahmed

Imperial Prostate @ip-london.bsky.social · Apr 29

Update of #IP9ATLAS presented by Archana Gopalakrishnan at #AUA25 🇺🇸

This pivotal RCT will evaluate MRI-based surveillance for patients with GG1-2 cancer starting active surveillance

Recruitment is open across the UK!

1 2

Reposted by Hashim Ahmed

Imperial Prostate @ip-london.bsky.social · Apr 29

That’s a wrap on #AUA25 for Team IP!

See you in Washington DC for #AUA26! 🇺🇸

1 2

Reposted by Hashim Ahmed

Imperial Prostate @ip-london.bsky.social · Apr 27

New publication alert! 🚨

A clinician survey on the current practices within the prostate cancer diagnostic pathway in the United Kingdom - Uma Walters et al (Journal of Clinical Urology)

🔗 doi.org/10.1177/2051...

2 3

Reposted by Hashim Ahmed

Imperial Prostate @ip-london.bsky.social · Apr 27

5yr outcomes following Rezum for >80mL prostates presented by @ajwlight.bsky.social (on behalf of Yan Leung) #AUA25 🇺🇸

Take home message - 3 of 4 patients were free of retreatment by 5 years

2 1

Reposted by Hashim Ahmed

Imperial Prostate @ip-london.bsky.social · Apr 27

Excellent podium presentation by our resident Chase Ng on >1200 patients in #RAPID discharged with negative MRI or biopsy

Only 1 in 12 developed csPCa & 1 in 20 needed cancer treatment by 5 years

More evidence of the oncological efficacy of pre-biopsy MRI! #AUA25 🇺🇸

1 3

Reposted by Hashim Ahmed

Imperial Prostate @ip-london.bsky.social · Apr 27

@ajwlight.bsky.social presents preliminary validation data on the #TARGET scoring system - good specificity and NPV for detecting GG2+ in-field disease

Watch this space for our definitive multi centre validation study! #AUA25 🇺🇸

2 1

Reposted by Hashim Ahmed

Imperial Prostate @ip-london.bsky.social · Apr 28

Building on our #IP8FLUORESCE study is #IB1LaserCOMPLETE - using ex vivo fluoresce confocal microscopy to establish muscle status in TURBT, presented by Archana Gopalakrishnan

Recruitment is under way - watch this space for results soon! #AUA25 🇺🇸

1 2

Reposted by Hashim Ahmed

Imperial Prostate @ip-london.bsky.social · Apr 28

In further #RAPID data, Chase Ng shows that patients discharged from a pre-biopsy MRI pathway with ASAP or HGPIN do not have a greater risk of subsequent csPCa or treatment than patients discharged without

#AUA25 🇺🇸

1 1

Reposted by Hashim Ahmed

Imperial Prostate @ip-london.bsky.social · Apr 27

Powerful messages from @londonprostate1.bsky.social in the focal therapy plenary crossfire debate

Most intermediate risk cases are suitable, focal therapy is very effective, and the functional outcomes are superior. Surgeon training is crucial!

#AUA25 🇺🇸

1 1 3

Reposted by Hashim Ahmed

Imperial Prostate @ip-london.bsky.social · Apr 28

Pilot results from #IP2ATLANTA on novel cytoreductive treatments to the prostate & mets in de novo mHSPC presented by @londonprostate1.bsky.social #AUA25 🇺🇸

Take home - these treatments are safe and justified

Recruitment for the main trial has completed - PFS endpoint to be reported 2027

1 1

Hashim Ahmed @londonprostate1.bsky.social · Apr 27

Thanks. Appreciate the kind words.

1

Reposted by Hashim Ahmed

Imperial Prostate @ip-london.bsky.social · Apr 2

📢 Join us at @IP_London

We are recruiting a Clinical Research Fellow to join the #IP13AVIDITY team: RCT evaluating the role of PSMA PET/CT in directing treatment in patients w/ high-risk PCa (closing 15/04)

🔗 www.imperial.ac.uk/jobs/search-...

@londonprostate1.bsky.social @connorurol.bsky.social

Description

Please note that job descriptions are not exhaustive, and you may be asked to take on additional duties that align with the key responsibilities ment...

www.imperial.ac.uk

2 2

Reposted by Hashim Ahmed

Imperial Prostate @ip-london.bsky.social · Mar 28

💬 #TRANSFORM will look at new ways of screening to reduce false positives, reduce biopsy rates and reduce diagnosing low risk cancers whilst finding more high risk cancers that need treating.

@londonprostate1.bsky.social @prostatecanceruk.bsky.social @nihr.bsky.social

www.lbc.co.uk/opinion/view...

I treat prostate cancer every day – now I'm launching a study that could transform screening and save lives

The debate on screening for prostate cancer has been raging for over two decades.

www.lbc.co.uk

1 2

Reposted by Hashim Ahmed

Prostate Cancer UK Professionals @prostateukprofs.bsky.social · Mar 28

Great to see Professor Hashim Ahmed @londonprostate1.bsky.social talking @nickferrarilbc.bsky.social through his PSA blood test this morning, and sharing why the TRANSFORM trial is vital for finding the best way to screen men for #ProstateCancer.

prostatecanceruk.org/research/tra...

Imperial Prostate @ip-london.bsky.social · Mar 28

💬 #TRANSFORM will look at new ways of screening to reduce false positives, reduce biopsy rates and reduce diagnosing low risk cancers whilst finding more high risk cancers that need treating.

@londonprostate1.bsky.social @prostatecanceruk.bsky.social @nihr.bsky.social

www.lbc.co.uk/opinion/view...

I treat prostate cancer every day – now I'm launching a study that could transform screening and save lives

The debate on screening for prostate cancer has been raging for over two decades.

www.lbc.co.uk

1 2

Hashim Ahmed @londonprostate1.bsky.social · Mar 27

Two weeks to go!
Imperial Prostate Masterclass
In association with Focal Therapy Society
@ip-london.bsky.social

www.imperialprostatemasterclass.org

1 3

Reposted by Hashim Ahmed

Imperial Prostate @ip-london.bsky.social · Mar 24

With presentations from 4 IP trials and multiple other projects, it’s been a fantastic #EAU25 for Imperial Prostate 🇪🇸

See you next year in London for #EAU26! 🇬🇧

1 1

Reposted by Hashim Ahmed

Imperial Prostate @ip-london.bsky.social · Mar 24

#IP2ATLANTA RCT pilot result #EAU25 🇪🇸

🔬 9 in 10 patients have a viable prostate tumour despite ADT+ARTA/Doce

🚦Early signal in prostate cancer mortality for cytoreductive arms

📈 Surgery, radiotherapy or ablation + SABR safe - Recruited (n=433) PFS exp.2027!

@connorurol.bsky.social

1 2

Reposted by Hashim Ahmed

Imperial Prostate @ip-london.bsky.social · Mar 24

It’s a big last day at #EAU25 for our team! 🇪🇸

@connorurol.bsky.social - 2x #IP2ATLANTA pilot study results (12:00)

Mr Chase Ng - #RAPID 5-yr follow-up for negative biopsy patients (12:05)

Mr Nikhil Mayor - #IP8FLUORESCE late breaking results (12:15)

1 1

Reposted by Hashim Ahmed

Imperial Prostate @ip-london.bsky.social · Mar 24

Mr Chase Ng presents 5-year follow-up data for patients discharged with negative MRI/biopsy from our #RAPID pathway #EAU25 🇪🇸

1 in 12 were subsequently diagnosed with GG2+ cancer and 1 in 20 needed treatment - this further highlights the efficacy of MRI-based diagnostics!

1 1

Reposted by Hashim Ahmed

Imperial Prostate @ip-london.bsky.social · Mar 24

Building on this morning’s #NeuroSAFE data, @nikhilmayor.bsky.social presents late-breaking results from #IP8FLUORESCE, assessing the diagnostic accuracy of FCM for detecting positive margins intra-op

Feasible, quick and good sensitivity and specificity for detecting margins ≥3mm!

#EAU25 🇪🇸

2 5

Hashim Ahmed @londonprostate1.bsky.social · Mar 23

Nice work by Deepika! #EAU2025 #EAU25

Imperial Prostate @ip-london.bsky.social · Mar 23

Lastly for Imperial Prostate today @ #EAU25 🇪🇸 is Ms Deepika Reddy in the new technologies & focal therapy in localised PCa session

Traditional risk classification strategies developed for radical treatment are not transferrable to focal therapy outcomes. Risk models are in development!

1

Reposted by Hashim Ahmed

Imperial Prostate @ip-london.bsky.social · Mar 23

Lastly for Imperial Prostate today @ #EAU25 🇪🇸 is Ms Deepika Reddy in the new technologies & focal therapy in localised PCa session

Traditional risk classification strategies developed for radical treatment are not transferrable to focal therapy outcomes. Risk models are in development!

2 2

Hashim Ahmed @londonprostate1.bsky.social · Mar 23

Well done Yan!
#eau25 #eau2025
Rezum a good option for men with slightly larger glands

Imperial Prostate @ip-london.bsky.social · Mar 23

Excellent presentation by Miss Yan Leung on 5-year outcomes after Rezum in >80mL prostates #EAU25 🇪🇸

75% retreatment-free at 5 years and the majority satisfied with their treatment!

1

Hashim Ahmed @londonprostate1.bsky.social · Mar 23

Great job by @nikhilmayor.bsky.social on the TRANSFORM article in European Urology Today congress news magazine

#EAU25 #EAU2025 @prostateukprofs.bsky.social
@uroweb.bsky.social

Imperial Prostate @ip-london.bsky.social · Mar 23

And now @londonprostate1.bsky.social presents an update on the #TRANSFORM randomised prostate cancer screening study in the plenary session - recruitment starting later this year to answer some of the biggest questions in screening 📝📈 #EAU25

1